|
|
|
| Radiofrequency ablation is an inferior option to liver resection for solitary hepatocellular carcinoma ≤ 5 cm without cirrhosis: A population-based study with stratification by tumor size |
| Song-Chen Dong a , b , # , Dou-Sheng Bai a , # , Fu-An Wang c , # , Sheng-Jie Jin a , Chi Zhang a , Bao-Huan Zhou a , Guo-Qing Jiang a , ∗ |
a Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou 225001, China
b Department of Hepatobiliary Surgery, The First Clinical College, Dalian Medical University, Dalian 116000, China
c Department of Interventional Radiology, Clinical Medical College, Yangzhou University, Yangzhou 225001, China
∗Corresponding author.
E-mail address: jgqing2003@hotmail.com (G.-Q. Jiang).
# Contributed equally. |
|
|
|
Abstract Background: About 10%-20% of all individuals who develop hepatocellular carcinoma (HCC) do not have cirrhosis. Comparisons are rarely reported regarding the effectiveness of radiofrequency ablation (RFA) and liver resection (LR) in survival of HCC without cirrhosis and stratification by tumor size ≤ 5 cm.
Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database and identified 1505 patients with a solitary HCC tumor ≤ 5 cm who underwent RFA or LR during 2004-2015. Patients were classified into non-cirrhosis and cirrhosis groups and each group was categorized into three subgroups, according to tumor size ( ≤30 mm, 31-40 mm, 41-50 mm).
Results: In patients without cirrhosis, LR showed better 5-year HCC cancer-specific survival than RFA in all tumor size subgroups ( ≤30 mm: 82.51% vs. 56.42%; 31-40 mm: 71.31% vs. 46.83%; 41-50 mm: 74.7% vs. 37.5%; all P < 0.05). Compared with RFA, LR was an independent protective factor for HCC cancer-specific survival in multivariate Cox analysis [ ≤30 mm: hazard ratio (HR) = 0.533, 95% confidence interval (CI): 0.313-0.908; 31-40 mm: HR = 0.439, 95% CI: 0.201-0.957; 41-50 mm: HR = 0.382; 95% CI: 0.159-0.916; all P < 0.05]. In patients with cirrhosis, for both tumor size ≤30 mm and 31-40 mm groups, there were no significant survival differences between RFA and LR in multivariate analysis (all P > 0.05). However, in those with tumor size 41-50 mm, LR showed significantly better 5-year HCC cancer-specific survival than RFA in both univariate (54.72% vs. 23.06%; P < 0.001) and multivariate analyses (HR = 0.297; 95% CI: 0.136-0.648; P = 0.002).
Conclusions: RFA is an inferior treatment option to LR for patients without cirrhosis who have a solitary HCC tumor ≤5 cm.
|
|
|
|
|
|
|
|
|
2023, Vol. 22 
